05.09.2018 CO.DON AG  DE000A1K0227

DGAP-News: CO.DON AG: CO.DON AG and Haemo Pharma GmbH sign contract for the distribution of Spherox in Austria


 
DGAP-News: CO.DON AG / Key word(s): Expansion CO.DON AG: CO.DON AG and Haemo Pharma GmbH sign contract for the distribution of Spherox in Austria 05.09.2018 / 07:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- CO.DON AG and Haemo Pharma GmbH sign contract for the distribution of Spherox in Austria Berlin / Teltow, 05 September 2018 - Yesterday CO.DON AG and Haemo Pharma GmbH signed a contract for the exclusive distribution in Austria of the EU-authorised, cell-based pharmaceutical Spherox, initially for a period of five years. For CO.DON AG, signing the distribution agreement means contractually agreed cash flows on a ascending annual scale, totalling around EUR 1 million at minimum in the business years 2018 and 2019. CO.DON will support Haemo Pharma GmbH during the entire distribution phase and will retain defined responsibilities. Ralf Jakobs, CEO of CO.DON AG, was very pleased with the result of the successful negotiations: "We are delighted that we and Haemo Pharma GmbH have been able to reach an effective and lucrative agreement for both of us, which will enable us and our partner to deliver an extremely successful market launch for our product in Austria and which forms the basis for a long-term partnership. Having signed this contract we are now in a position to present a stable and secure monetary result for the Austrian market too, even before the forthcoming adequate reimbursement of our product takes effect. This is in line with our strategy of only offering our product in markets with reasonable pricing and reimbursement policies. Furthermore, we see the Austrian market as the starting point for opening up selected eastern European markets, where we will also be looking for distribution partners." CO.DON AG develops, produces and markets autologous cell therapies for the minimally-invasive repair of cartilage damage in the knee joint following traumatic or degenerative defects. Spherox is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). The treatment has been used in over 200 clinics to treat more than 14,000 patients. The company received EU marketing authorisation for Spherox in July 2017. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs. Further information is available from www.codon.de Investor Relations and Press Contact: Matthias Meißner, M.A. Corporate communications / IR / PR Tel. +49 (0)30 240352330 Fax +49 (0)30 240352309 Email: ir@codon.de --------------------------------------------------------------------------- 05.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: CO.DON AG Warthestraße 21 14513 Teltow Germany Phone: 03328 43460 Fax: 03328 434643 E-mail: info@codon.de Internet: www.codon.de ISIN: DE000A1K0227 WKN: A1K022 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 720665 05.09.2018


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 2,69 3,62 4,48 5,09 5,60 5,96 5,65 8,80
EBITDA1,2 -2,24 -2,50 -2,27 -2,61 -3,41 -6,73 -7,84 0,00
EBITDA-Marge3 -83,27 -69,06 -50,67 -51,28 -60,89 -112,92 -138,76 0,00
EBIT1,4 -2,38 -2,68 -2,48 -2,86 -3,65 -6,98 -8,56 0,00
EBIT-Marge5 -88,48 -74,03 -55,36 -56,19 -65,18 -117,11 -151,50 0,00
Jahresüberschuss1 -2,38 -2,68 -2,49 -2,87 -3,65 -7,05 -6,27 0,00
Netto-Marge6 -88,48 -74,03 -55,58 -56,39 -65,18 -118,29 -110,97 0,00
Cashflow1,7 -2,33 -1,56 -1,78 -2,97 -3,62 -5,88 -8,14 0,00
Ergebnis je Aktie8 -0,22 -0,24 -0,18 -0.18 -0,21 -0,36 -0,55 -0,74
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
co.don
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1K022 2,240 54,42
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,000 -6,58
KBV KCV KUV EV/EBITDA
3,20 - 9,63 -5,636
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
Hauptversammlung
0,00 0,00 0,00 12.06.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.08.2019 30.04.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-15,95% -39,51% -29,45% -44,90%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu CO.DON AG  ISIN: DE000A1K0227 können Sie bei DGAP abrufen

Biotechnologie , A1K022 , CNWK , XETR:CNWK